<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00530179</url>
  </required_header>
  <id_info>
    <org_study_id>0307003</org_study_id>
    <nct_id>NCT00530179</nct_id>
  </id_info>
  <brief_title>FDG-PET-Stratified R-DICEP and R-Beam/ASCT For Diffuse Large B-Cell Lymphoma</brief_title>
  <acronym>PET-Chop</acronym>
  <official_title>FDG-PET-Stratified R-DICEP and R-BEAM/ASCT For Diffuse Large B-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AHS Cancer Control Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AHS Cancer Control Alberta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate:&#xD;
&#xD;
        1. whether an imaging test called a PET (Positron emission tomography) scan performed after&#xD;
           two cycles of standard chemotherapy is able to identify patients who have a high cure&#xD;
           rate after completing standard chemotherapy alone; and&#xD;
&#xD;
        2. whether high dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT)&#xD;
           when used in combination with an antibody called Rituximab results in high cure rates&#xD;
           for those patients predicted to do poorly with standard chemotherapy by the PET scan.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND AND RATIONALE:&#xD;
&#xD;
      Although the addition of Rituximab anti-CD20 monoclonal antibody therapy to standard CHOP&#xD;
      chemotherapy (R-CHOP) results in a 15-20% increase in absolute EFS rate over CHOP alone for&#xD;
      DLBCL patients, it is likely that 40-50% of patients with poor prognosis DLBCL will not be&#xD;
      cured by R-CHOP. High dose chemotherapy (HDCT) and autologous stem cell transplantation&#xD;
      (ASCT) has been shown to salvage a substantial proportion of patients with relapsed DLBCL. A&#xD;
      meta-analysis of randomized controlled trials comparing standard-dose chemotherapy (SDCT)&#xD;
      alone to SDCT followed by HDCT/ASCT as initial treatment for poor prognosis DLBCL&#xD;
      demonstrated a significant benefit for HDCT over SDCT in terms of EFS and OS. A single centre&#xD;
      prospective phase II study was conducted in Calgary to assess feasibility, toxicity, and&#xD;
      efficacy of two cycles of HDCT following just one cycle of CHOP induction therapy for&#xD;
      patients under 65 years of age who were diagnosed with aggressive histology lymphoma and 2-3&#xD;
      Age Adjusted International Prognostic Index (AAIPI) risk factors. The study was conducted&#xD;
      prior to the widespread use of Rituximab plus CHOP (R-CHOP). The treatment protocol involved&#xD;
      one cycle of standard dose CHOP followed by one cycle of dose-intensive cyclophosphamide 5.25&#xD;
      g/m2, etoposide 1.05 g/m2, cisplatin 105 mg/m2 (DICEP), then autologous blood stem cell&#xD;
      collection, followed by one cycle of high dose BCNU 300 mg/m2, etoposide 800 mg/m2, Ara-C&#xD;
      1600 mg/m2, melphalan 140 mg/m2 (BEAM) and autologous stem cell transplantation (ASCT) and&#xD;
      radiotherapy to prior bulk. With a median follow up of 49 months, 4 year event free (EFS) and&#xD;
      overall survival (OS) rates for the 55 patients accrued to the study were 72% (95% CI=60-84%)&#xD;
      and 79% (95% CI=69-90%), respectively.&#xD;
&#xD;
      The two major advances in lymphoma management that have occurred since the design of our&#xD;
      CHOP-DICEP-BEAM/ASCT phase II study are the addition of Rituximab anti-CD20 monoclonal&#xD;
      antibody therapy to chemotherapy (as described above), and the use of FDG-PET functional&#xD;
      imaging/response assessment. Several studies have reported the strong correlation of early&#xD;
      response assessment using FDG-PET with PFS and OS following standard chemotherapy for&#xD;
      aggressive NHL. In one of the largest, best designed studies, PET-negativity following 2&#xD;
      cycles of RCHOP was associated with higher 2-year estimates of EFS (82% vs 43% , p &lt; .001)&#xD;
      and OS (90% vs 61%, p = .006). The incorporation of Rituximab and PET-guided HDCT/ASCT into&#xD;
      our intensive chemotherapy protocol may lead to further improvements in EFS while decreasing&#xD;
      the overall need for HDCT/ASCT by targeting those patients destined to fail R-CHOP by early&#xD;
      PET-based response assessment.&#xD;
&#xD;
      STUDY OBJECTIVES:&#xD;
&#xD;
        1. To determine if negative FDG-PET imaging following 2 cycles of R-CHOP chemotherapy is&#xD;
           able to identify a group of patients with excellent prognosis (80% 3-year EFS) following&#xD;
           standard 6 cycles of R-CHOP chemotherapy alone.&#xD;
&#xD;
        2. To determine if a group of patients with positive FDG-PET imaging following 2 cycles of&#xD;
           R-CHOP chemotherapy are able to achieve excellent outcome (80% 3-year EFS) following&#xD;
           intensive chemotherapy with R-DICEP and R-BEAM/ASCT.&#xD;
&#xD;
        3. To determine if PET-guided R-DICEP and R-BEAM/ASCT is feasible and associated with&#xD;
           acceptable toxicity rates in a multi-centre study.&#xD;
&#xD;
      STUDY DESIGN:&#xD;
&#xD;
      INCLUSION CRITERIA:&#xD;
&#xD;
        1. Give written informed consent&#xD;
&#xD;
        2. Age 18-65 years&#xD;
&#xD;
        3. Histological diagnosis of Diffuse Large B-cell Lymphoma including:&#xD;
&#xD;
             1. Diffuse Large B-cell&#xD;
&#xD;
             2. Immunoblastic B-cell&#xD;
&#xD;
             3. Primary Mediastinal Diffuse Large B-cell&#xD;
&#xD;
             4. T-cell Rich, Diffuse Large B-cell&#xD;
&#xD;
             5. Anaplastic Large B-Cell&#xD;
&#xD;
             6. Diffuse Large B-cell with areas of follicular lymphoma in same biopsy&#xD;
&#xD;
        4. No central nervous system involvement by lymphoma&#xD;
&#xD;
        5. No more than 1 prior cycle of R-CHOP chemotherapy&#xD;
&#xD;
        6. At least 1 adverse International Prognostic Index factor at diagnosis:&#xD;
&#xD;
           a. Age &gt; 60 years b. ECOG performance status 2-4 c. Elevated serum LDH level d. More&#xD;
           than 1 extranodal site involved by lymphoma e. Stage 3 or 4&#xD;
&#xD;
        7. Adequate organ function:&#xD;
&#xD;
             1. Cardiac: LVEF &gt;45%&#xD;
&#xD;
             2. Pulmonary: FVC, FEV1 and DLCO &gt;50% predicted&#xD;
&#xD;
             3. Renal: creatinine &lt;120µmol/L unless caused by ureteric obstruction from lymphoma&#xD;
&#xD;
             4. Liver: ALT, AlkP, Bilirubin &lt;3 x upper limit of normal unless caused by biliary&#xD;
                tract obstruction from lymphoma&#xD;
&#xD;
                EXCLUSION CRITERIA:&#xD;
&#xD;
                1. Histological diagnosis other than Diffuse Large B-cell Lymphoma 2. Pregnant or&#xD;
                lactating females 3. Concurrent use of other anti-cancer therapies 4. Other serious&#xD;
                co-morbid illness that would compromise study participation. 5. Prior malignancy&#xD;
                unless non-melanoma skin cancer, carcinoma in-situ of the cervix (CIN) or breast,&#xD;
                or malignancy treated more than 5 years previously with no evidence of recurrent&#xD;
                disease since initial treatment.&#xD;
&#xD;
                6. More than 1 prior cycle of Rituximab, cyclophosphamide, or doxorubicin. 7. Prior&#xD;
                HDCT/ASCT or prior radiotherapy.&#xD;
&#xD;
                STUDY ENDPOINTS&#xD;
&#xD;
                Primary:&#xD;
&#xD;
                • 3 year EFS for patients receiving 6 cycles R-CHOP (PET-negative response) and for&#xD;
                patients receiving RCHOP x2 followed by R-DICEP then R-BEAM/ASCT (PET-positive&#xD;
                response)&#xD;
&#xD;
                Secondary:&#xD;
&#xD;
                • Complete and Partial Response Rates&#xD;
&#xD;
                • PET/CT response rates following RCHOP x 2 cycles&#xD;
&#xD;
                • Overall Survival&#xD;
&#xD;
                  -  Safety (type, frequency, severity, and relationship of adverse events to study&#xD;
                     treatment)&#xD;
&#xD;
                STUDY DURATION: Three years TOTAL SAMPLE SIZE: 70-80 patients&#xD;
&#xD;
                DOSING REGIMEN(S):&#xD;
&#xD;
        1. Induction: Standard R-CHOP chemotherapy q21days x 2 cycles&#xD;
&#xD;
           R-CHOP x 2 cycles q21days:&#xD;
&#xD;
           Rituximab 375mg/ m2 IV day 1 Cyclophosphamide 750mg/ m2 IV day 1 Adriamycin 50mg/ m2 IV&#xD;
           day 1 Vincristine 1.4mg/ m2 (max 2mg) IV day 1 Prednisone 100mg po days 1-5&#xD;
&#xD;
        2. FDG-PET/CT imaging between days 10-15 following R-CHOP cycle #2.&#xD;
&#xD;
      Sites of disease will be scored for intensity based on the following scale:&#xD;
&#xD;
        1. Absent&#xD;
&#xD;
        2. Minimal (low grade but greater than in regional lymph nodes of similar size or&#xD;
           surrounding interstitial tissues)&#xD;
&#xD;
        3. Low (readily visible but less than liver)&#xD;
&#xD;
        4. Medium (comparable to liver)&#xD;
&#xD;
        5. High (greater than liver)&#xD;
&#xD;
           Interim post therapy scans will be considered as negative (showing a favorable response)&#xD;
           if no more than one site shows an intensity score of greater than 3.&#xD;
&#xD;
           The treatment protocol will be dictated by the result of the interim FDG-PET/CT scan&#xD;
           following 2 cycles of R-CHOP chemotherapy as follows:&#xD;
&#xD;
             1. If FDG-PET scan negative: 4 more cycles R-CHOP (total 6 cycles R-CHOP)&#xD;
&#xD;
             2. If FDG-PET scan positive: one cycle of R-DICEP then within 5-8 weeks administer&#xD;
                R-BEAM and autologous blood stem cell transplantation as outlined below:&#xD;
&#xD;
                3) For PET-positive patients ONLY:&#xD;
&#xD;
           R-DICEP CHEMOTHERAPY (begin 3-5 weeks following day 1 CHOP #2).&#xD;
&#xD;
           ½NS+20meq KCL/L IV at 150ml/h start 19:00h day 1 then decrease to 75ml/h at 08:00am day&#xD;
           2, continue to day 5 Rituximab 375mg/m2 IV day 1 and 8 (day 1 on a Wednesday)&#xD;
           Cyclophosphamide 1.75 g/ m2 d2,3,4 in 500ml D5W over 2 hrs Etoposide 350 mg/ m2 d2,3,4&#xD;
           in 1 L over 2 hrs daily Cisplatin 35 mg/m2 d2,3,4 in 500ml N/S +25g mannitol over 2 hrs&#xD;
           Mesna 1.75g/m2 d2,3,4 by continuous infusion over 24 hrs G-CSF 300 (&lt;70kg), 480&#xD;
           (70-100kg), or 600mcg/d (&gt;100kg) SC from day 15 until apheresis completed&#xD;
&#xD;
           AUTOLOGOUS BLOOD STEM CELL COLLECTION:&#xD;
&#xD;
           Apheresis approximately day 20-22 of R-DICEP, after ANC&gt;5 x 109/L, platelets increasing&#xD;
           &gt;50 x109/L , and peripheral blood CD34 count &gt;20 x106/L (if measurement available).&#xD;
           Apheresis to proceed according to standards set at each study centre until at least&#xD;
           3x106CD34+ cells/kg have been collected (&gt;5x106 CD34+ cells/kg preferred).&#xD;
&#xD;
           R-BEAM + Autologous Stem Cell Transplantation (5-8weeks post-d1 R-DICEP)&#xD;
&#xD;
           Day - 6 Rituximab 375mg/m2 IV BCNU 300mg/m2 IV Day -5 to -2 Etoposide 100mg/m2 IV q12h x&#xD;
           8 doses Ara-C 200mg/m2 IV q12h x 8 doses Day -1 Melphalan 140mg/m2 IV Day 0 Stem Cell&#xD;
           Infusion Day 14 Rituximab 375mg/m2 IV&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">May 19, 2015</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard R-CHOP chemotherapy every 21 days X 2 Cycles followed by PET/CT scan. If scan is determined negative for disease intensity patient receives 4 more cycles R-CHOP (total 6 cycles R-CHOP)&#xD;
Assigned interventions: Drug: R-CHOP (Rituximab, Cyclophosphamide, Etoposide, Cisplatin, Mesna, G-CSF 6 - 21 DAY Cycles of R-CHOP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard R-CHOP chemotherapy every 21 days X 2 Cycles followed by PET/CT scan. If scan is determined positive for disease intensity the patient receives one cycle or R-DICEP/R-BEAM the autologous blood stem cell transplantation.&#xD;
Assigned Interventions: Procedure/Surgery: Autologous Blood Stem Transplantation 2 CYCLES OF R-CHOP + R-DICEP/R-BEAM FOLLOWED BY AUTOLOGOUS BLOOD STEM CELL TRANSPLANTATION</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Blood Stem Transplantation</intervention_name>
    <description>2 CYCLES OF R-CHOP + R-DICEP/R-BEAM FOLLOWED BY AUTOLOGOUS BLOOD STEM CELL TRANSPLANTATION</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-CHOP</intervention_name>
    <description>6 - 21 DAY Cycles of R-CHOP</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-65 years&#xD;
&#xD;
          -  Diagnosis of Diffuse Large B-Cell Lymphoma&#xD;
&#xD;
          -  Adverse Prognosis = Stage 3 or 4 and elevated LDH&#xD;
&#xD;
          -  No more than one prior cycle of R-CHOP chemotherapy&#xD;
&#xD;
          -  Adequate cardiac function&#xD;
&#xD;
          -  No central nervous system involvement by lymphoma&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Histological diagnosis other than Diffuse Large B-cell Lymphoma&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Use of other anti-cancer therapies&#xD;
&#xD;
          -  Other serious illness that would compromise study participation&#xD;
&#xD;
          -  Prior malignancy&#xD;
&#xD;
          -  Prior stem cell transplant or radiotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas Stewart, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>AHS Cancer Control Alberta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T4C 2H5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa General Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saskatchewan Cancer Agency</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>September 13, 2007</study_first_submitted>
  <study_first_submitted_qc>September 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2007</study_first_posted>
  <last_update_submitted>January 17, 2019</last_update_submitted>
  <last_update_submitted_qc>January 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AHS Cancer Control Alberta</investigator_affiliation>
    <investigator_full_name>Douglas Stewart</investigator_full_name>
    <investigator_title>Dr. Douglas Stewart - Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Diffuse Large B-Cell Lymphoma</keyword>
  <keyword>Positron Emission Tomography</keyword>
  <keyword>CHOP Chemotherapy protocol</keyword>
  <keyword>Stem Cell Transplantation</keyword>
  <keyword>Fluorodeoxyglucose F18</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

